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ABSTRACT 
 
Purpose: The goal of the Determining Risk of Vascular Events by Apnea Monitoring 
(DREAM) Study is to develop a prognostic model for cardiovascular outcomes, based on 
physiologic variables—related to breathing, sleep architecture, and oxygenation—
measured during polysomnography in U.S. veterans.  
Methods: The DREAM Study is a multi-site, retrospective observational cohort study 
conducted at three Veterans Affairs (VA) centers (West Haven, CT; Indianapolis, IN; 
Cleveland, OH). Veterans undergoing polysomnography between January 1, 2000 and 
December 31, 2004 were included based on: referral for evaluation of sleep-disordered 
breathing; documented history and physical prior to sleep testing; and ≥2 hours sleep 
monitoring. Demographic, anthropomorphic, medical, medication, and social history 
factors were recorded. Measures to determine sleep apnea, sleep architecture, and 
oxygenation were recorded from polysomnography. VA Patient Treatment File, VA–
Medicare Data, Vista Computerized Patient Record System, and VA Vital Status File 
were reviewed on dates subsequent to polysomnography, ranging from 0.06 to 8.8 years 
(5.5±1.3 yrs; mean±SD).  
Results: The study population includes 1,840 predominantly male, middle-aged 
veterans. As designed, the main primary outcome is the composite endpoint of acute 
coronary syndrome, stroke, transient ischemic attack or death. Secondary outcomes 
includes incidents of neoplasm, congestive heart failure, cardiac arrhythmia, diabetes, 
depression, and post-traumatic stress disorder. Laboratory outcomes include measures 
of glycemic control, cholesterol, and kidney function. (Actual results are pending.) 
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Conclusions: This manuscript provides the rationale for the inclusion of veterans in a 
study to determine the association between physiologic sleep measures and 
cardiovascular outcomes, and specifically the development of a corresponding 
outcomes-based prognostic model.  
Keywords: sleep apnea; OSA; epidemiology; veterans; cardiovascular 
 
 
INTRODUCTION 
 A recent Institute of Medicine report, entitled ‘Sleep Disorders and Sleep 
Deprivation: an Unmet Public Health Challenge’, estimated that 50-70 million 
Americans suffer from a chronic sleep disorder [1]. Major aspects of this “unmet public 
health challenge” are the cardiovascular and cerebrovascular health consequences of 
sleep-disordered breathing. Obstructive sleep apnea (OSA), a common form of sleep-
disordered breathing, has a high and rising prevalence (17%) in the general adult 
population, attributable in part to enhanced awareness and the emerging epidemic of 
obesity [2-4]. OSA has also been independently linked to important health outcomes, 
including hypertension [5], fatal and nonfatal cardiovascular events [6, 7], stroke[8], 
and metabolic dysfunction [9].   
 The prevalence of OSA is believed to be even higher among U.S. veterans [10, 11], 
due to major risk factors for OSA that are common in this population (e.g. increasing 
age, male gender, obesity, and alcohol use) [12]. Furthermore, because of a high 
prevalence of other cardiovascular risk factors and metabolic co-morbidities, veterans 
may be more vulnerable to some of the health consequences of OSA [13]. Accordingly, 
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significant resources are now being dedicated in the Veterans Health Administration to 
improving access to the diagnosis of OSA.  
 Although significant efforts are being made to increase diagnostic capacity, our 
understanding of the polysomnographic measures that best predict the adverse health 
consequences of OSA remains poorly developed. OSA is characterized  by repeated 
upper airway occlusion during  sleep which results in airflow cessation (apnea) or 
reduction (hypopnea). The enumeration of these events-per-hour of sleep yields the 
apnea-hypopnea index (AHI). Clinically, this metric defines sleep apnea severity, but it 
has also been shown to relate to cardiovascular disease, including hypertension [5], 
coronary heart disease [14], and stroke[8]. Standard polysomnography also records a 
rich array of other physiologic measurements. Although the AHI is important, as a 
single metric, it does not take into account other physiologic factors, such as oxygen 
desaturation severity, overall arousal frequency, cardiac arrhythmia, or degree of sleep 
disruption.  
 Embedded within the collection of various physiologic polysomnographic 
components lies information that may predict adverse health outcomes more accurately 
than the AHI. Measurements of physiologic components other than breathing—
including sleep disruption, heart rate variability, or periodically occurring limb 
movements—have been shown to track with hypertension and cardiovascular disease 
[15-17]. Previous research, however, has not adequately integrated these diverse 
physiologic measures to evaluate potential cardiovascular associations in a combined 
approach; instead, most studies have focused on singular measures, usually AHI.  A gap 
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in knowledge, therefore exists regarding how different physiologic factors measured 
during sleep, when “combined,” may be associated with disease outcomes. 
 The goal of the Determining Risk of Vascular Events by Apnea Monitoring 
(DREAM) Study is to develop a prognostic model for cardiovascular and mortality 
outcomes, based on physiologic variables measured during polysomnography in U.S. 
veterans. The DREAM study is composed of a large U.S. veteran study population that 
has undergone in-laboratory polysomnography for suspected sleep-disordered 
breathing and has been followed for the development of cardiovascular disease and 
mortality.  The objectives of this manuscript are to: describe the goals of the DREAM 
study; outline its methodological approach; and provide the rationale for the inclusion 
of U.S. veteran patients undergoing polysomnography for suspected sleep disordered 
breathing. 
 
DESIGN AND METHODS 
 
Overall Trial Design/Specific Aims 
 The DREAM Study is a multi-site, retrospective, observational cohort study. The 
primary objectives of the DREAM Study are to determine the polysomnographic 
variables that are most predictive of incident cardiovascular outcomes. The DREAM 
Study includes data from three Veterans Health Administration (VHA) medical centers 
(West Haven, CT; Indianapolis, IN; Cleveland, OH). The Institutional Review Boards at 
each of the sites approved the conduct of this research. 
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At the time of the sleep study, medical, anthropomorphic and demographic 
characteristics were abstracted from the VA electronic medical record for visits most 
recent (and prior to) the sleep study.  Data from the sleep study were also abstracted at 
this time. All medical record and polysomnographic abstraction was performed at the 
central clinical research center at the Clinical Epidemiology Research Center (CERC) at 
the West Haven VA. (The CERC is a collaboration among the VA Cooperative Studies 
Program, VA Connecticut Healthcare System, and Yale University which seeks to 
improve the healthcare of U.S. veterans by coordinating and supporting nationally 
funded VA research involving large observational cohorts.)  
 The DREAM study was designed and collected with the overall goal of developing 
a clinical prognostic model of cardiovascular disease in patients undergoing sleep 
testing for suspected sleep disordered breathing, and who are at risk for developing such 
events. The initial aim of this study was to identify polysomnographic and sleep 
measures—including AHI, oxygen desaturation frequency, arousal index and periodic 
limb movement index—that best predict incidence of stroke, acute coronary syndrome 
and mortality. With the identification of polysomnography-related cardiovascular risk 
variables from the DREAM study, the subsequent aim was to validate this model in a 
non-veteran observational cohort of patients studied with polysomnography for sleep-
disordered breathing. The final aim was to determine to what degree do 
polysomnography-related measures add to the prognostic value of more conventional 
risk factors of cardiovascular disease, including smoking, hypertension, diabetes, age, 
hyperlipidemia, and alcohol use.        
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Inclusion and Exclusion Criteria    
            U.S. veterans undergoing in-laboratory polysomnography for the evaluation of 
sleep-disordered breathing between January 1, 2000 and December 31, 2004 were 
eligible for inclusion (Table 1). Eligible patients included those referred for suspected 
sleep-disordered breathing who had a history and physical documented in the electronic 
medical record prior to the sleep study, and who underwent at least 2 hours of attended 
sleep monitoring using full polysomnography (full night or split night protocols). The 
inclusion of veterans undergoing split night studies in the cohort reflects the wide use of 
combined diagnostic and therapeutic sleep testing throughout the VA system. Patients 
were excluded if: they were referred for reasons other than the evaluation of suspected 
sleep-disordered breathing (e.g., narcolepsy or movement disorder); the study was done 
with a tracheostomy that was “open” or “unplugged”; or the study was performed 
entirely with airway pressurization. Veterans were not excluded if they received therapy 
by oral appliance or surgery. 
  
Polysomnography Data Acquisition 
            Digital in-laboratory polysomnographic data from the Indianapolis, Cleveland, 
and West Haven VAMCs, from 01/01/2000 through 12/31/04 (n=1840 out of 
approximately 2,200 available) were rescored by an independent certified sleep 
technologist at the CERC in West Haven. Participants underwent overnight, attended, 
in-laboratory polysomnography, which included at least 2 hours of sleep without 
positive airway pressure (PAP) utilization. Polysomnogram acquisition software 
included Grass data-acquisition systems (Astro-Med; Warwick, RI) for West Haven, 
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CompuMedics PS (Melbourne, Australia) for Indianapolis, and Embla (Pleasanton, CA) 
for Cleveland.   
 The recording montage included frontal (F3, F4), central (C3, C4) and occipital 
(O1, O2) electrodes referenced to contralateral auricular leads, bilateral 
electrooculographic channels, 2 submental electromyographic channels, 
electrocardiography, nasal pressure transduction, oronasal thermistry, chest/abdomen 
respiratory inductance plethysmography, finger pulse oximetry, body position (by a 
mercury gauge sensor), and bilateral anterior tibialis electromyography.  
Sleep stages were scored using 30-second epochs according to Rechtschaffen and 
Kales criteria [18, 19]. and sleep architecture variables were noted as percent total sleep 
time for stages NREM 1, NREM 2, NREM 3, and REM sleep. Arousals were scored 
according to published guidelines and summarized as the total number of arousals per 
hour of sleep (arousal index) [20].  
Apnea was defined as near complete reduction in thermocouple, lasting longer 
than 10 seconds, and was classified as obstructive or central depending on whether 
respiratory effort was present or absent, respectively. Hypopnea was scored according to 
American Academy of Sleep Medicine (AASM) recommended: ≥30% decrement in 
amplitude of nasal pressure flow signal for at least 10 seconds associated with a 4% 
oxygen desaturation,  and alternative criteria: ≥50% decrement in amplitude of nasal 
pressure flow signal for at least 10 seconds associated with a 3% oxygen desaturation or 
arousal, based upon criteria accepted at the time of scoring.[19]   
Apneas and hypopneas were categorized as obstructive or central based on AASM 
criteria. The apnea-hypopnea index (AHI) was calculated as the total number of apneas 
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and hypopneas per hour of sleep. Nocturnal pulse oximetry was used to measure 
oxygenation, and oxygen saturation was noted as the number of 3% desaturations per 
hour of sleep, oxygen desaturation 3% index; and 4% desaturations per hour of sleep, 
oxygen desaturation 4% index. Oxygenation was further measured as percent of total 
sleep time spent below 90% saturation. Periodic limb movements were scored according 
to AASM guidelines: 8µV increase in anterior tibialis EMG amplitude from baseline for 
0.5 to 10.0 seconds, occurring a minimum of four movements in succession, no less and 
no more than 5 and 90 seconds apart, respectively [19]. The periodic limb movement 
index (PLMI) was computed as the total number of periodic leg movements per hour of 
sleep. 
The different sleep-related polysomnographic and questionnaire variables are 
displayed in Table 2.  
 
Designation of Sleep Apnea Treatment   
For patients in this VA cohort, treatment was recommended according to 
consensus guidelines, and appliances and supplies were ordered by the institution 
through a single respiratory supply service. Importantly, the orders for these services 
are documented in the electronic medical record. In addition, patients are followed 
closely for the assessment of efficacy and treatment compliance through established 
sleep medicine and pulmonary clinics where positive airway pressure use is 
documented. Two physician investigators, blinded to outcome status, categorized each 
patient’s airway pressurization treatment use in categories of: (1) not ordered; (2) no 
use; (3) intermittent use; and (4) continuous or “regular” use of positive airway 
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pressure. For the purposes of these analyses, airway pressurization compliance was 
documented into (1) “regular use” or (2) “not regular use”. “Regular use was 
approximated by the Centers of Medicare & Medicaid definition of CPAP compliance of 
4 hours per night for 70% of nights or by regular issuance of supplies. It should be noted 
that many of the times, such precise data were not available for compliance, as CPAP 
use was information was provided by patient self-report then further by provider 
documentation of this.   
 
Covariates  
 A distinctive feature of this study is the use of the robust VA databases across 
different VA sites, taking advantage of the centralized electronic medical record [Vista 
Computerized Patient Record System (CPRS/Vista Web)] that is shared by each of the 
sites. Experienced and trained research staff, blinded to study hypotheses, manually 
abstracted demographic, anthropomorphic and medical data. Covariate data is listed in 
Table 3. Baseline data were abstracted from clinical visits directly preceding the 
polysomnography date (time zero), and included measurements of age, sex, race, height, 
weight, blood pressure, smoking status (yes, no, pack years), and alcohol use (yes, no).  
Past medical history was also abstracted, including histories of: hypertension, 
hyperlipidemia, congestive heart failure, cardiac arrhythmia (atrial fibrillation/flutter, 
second degree atrioventricular block, third degree atrioventricular block, QT 
prolongation), pacemaker, percutaneous angioplasty, coronary artery bypass graft, 
angina, arterial claudication, stroke, transient ischemic attack, diabetes, end stage renal 
disease, human immunodeficiency virus, cancer (and type), dementia, depression, and 
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post-traumatic stress disorder. Using this information, the Charlson Comorbidity Index 
was calculated for each patient [21].  
Medical data at baseline also included three clinical blood pressure 
measurements (occurring on three consecutive clinical visits), cardiac echocardiography 
(if completed), electrocardiography, and several laboratory values: two fasting blood 
glucose values, hemoglobin A1c, total cholesterol, HDL cholesterol, LDL cholesterol, 
creatinine, blood urea nitrogen, and thyroid stimulating hormone levels. Medications 
were also inventoried, with doses of anti-hypertensive medication noted.    
 
Primary Outcomes 
 Follow-up events that occurred any time from time zero (polysomnography day) 
through the date of participant’s last visit were included, so that participants had follow-
up ranging from 0.06 to 8.8 years (5.5 ± 1.3 yrs; mean±SD). The main primary outcome 
is the composite endpoint of acute coronary syndromes, stroke, transient ischemic 
attack or death (Table 4) [22]. The choice of composite endpoint is based on an accepted 
methodological practice; when outcomes are hierarchic, lower order events (stroke, 
myocardial infarction) should be assessed with higher order ones (death) to avoid 
inferential errors (e.g., people who die can no longer have cardiovascular events) [23].  
Acute coronary syndrome, stroke, and death events were ascertained by review of 
the VA Patient Treatment File, VA Outpatient Clinic File, VA–Medicare Data, the Vista 
Computerized Patient Record System (CPRS/Vista Web), and the VA Vital Status File. 
The VHA Patient Treatment File (PTF=inpatient) and Patient Clinic Encounter 
(PCE=outpatient) were searched for appropriate  International Classification of 
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Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes  for TIA/stroke 
(434.XX, 435.X, and 436) and acute coronary syndrome (410.XX excluding history code 
411). These codes are both sensitive and specific for the diagnosis of stroke and ACS 
[24]. Overall mortality was ascertained using the VA Vital Status File; this file combines 
death dates from several sources including the Patient Treatment File, Beneficiary 
Identification and Record Locator Subsystem death file, Medicare Vital Status, and 
Social Security Administration Death File. Mortality was further divided into fatal 
events attributable to myocardial infarction, stroke, cardiac arrest, arrhythmia, 
congestive heart failure, cancer, or suicide.  
Secondary outcomes included incidents of neoplasm, congestive heart failure, 
cardiac arrhythmia, peripheral vascular disease, end stage renal disease, pulmonary 
hypertension, deep vein thrombosis, diabetes, human immunodeficiency virus, 
dementia, depression, and post-traumatic stress disorder. Laboratory outcomes 
included measures of glycemic control, including hemoglobin A1c and fasting glucose 
levels, total cholesterol, HDL cholesterol, LDL cholesterol, creatinine, blood urea 
nitrogen, and thyroid stimulating hormone levels.  
 All outcomes were adjudicated by an internal medicine trained physician who 
verified their occurrence by reviewing the medical record.  Exact times of each of the 
events, including death, were recorded. Time-to-event was defined as the time from 
overnight polysomnography (time zero) to the time of a patient’s confirmed first 
cardiovascular event (CHD or stroke) or death, or to the end of follow-up (10/14/2011). 
Patients not found to have had a vascular event or death, and who had not been seen in 
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an outpatient visit since the end of follow-up (12/31/07), were censored at the last point 
of contact (e.g., last outpatient visit). 
   
Sampling and Sample Size 
 Participants were included based upon their completion of an attended overnight 
sleep study for the evaluation of sleep-disordered breathing. Given that both 
Indianapolis and West Haven VA participants were predominantly Caucasian, the 
Cleveland VA was chosen specifically to broaden inclusion of minorities, in particular 
African-Americans. Prevalent cardiovascular disease and hypertension were not 
excluded; this approach allows for a determination of whether primarily incident 
disease differs from secondary or recurrent disease.  
The source population includes approximately 2,200 veterans at VA Connecicut 
Healthcare System (N~800),  the Richard L. Roudebush Indianapolis VAMC (N~900), 
and the Louis Stokes Cleveland VAMC (N~500). Based on an accrual interval of 4 years, 
a mean follow-up interval of 5 years, and a median time to event of 3 years (estimated 
from previous work) a sample size of 2200 allows for a minimal detectable hazard ratio 
of 1.15 with 80% power and α=0.05 [8]. The study is therefore powered adequately to 
detect an association between individual sleep variables and the development of acute 
coronary syndrome (which represents the most conservative estimate of the three 
primary endpoints). For patients in the DREAM study, the mortality rate is 13.2%.For 
the general male population aged 60 years (in DREAM study, 94.4% are male and 
average age is 58.1 years old), the mortality rate is 1.1% 
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(www.ssa.gov/oact/STATS/table4c6.html).[25] Based on the above information, the 
standardized mortality ratio is 13.2/1.1= 12.0.  
From this approximately 2,200 available participants, demographic, medical, and 
polysomnographic data have been abstracted for 1,840 veterans. Table 5 outlines some 
baseline demographic and abbreviated polysomnographic characteristics of the cohort.  
 
DISCUSSION 
 
 The DREAM Study is a multi-site, retrospective, observational cohort study 
designed to determine if various physiologic sleep study variables predict cardiovascular 
events, such as stroke, CHD or mortality. This research is based upon the growing need 
to identify therapeutic targets to reduce cardiovascular disease, the leading cause of 
mortality in the United States [26]. Better understanding the connection between OSA 
and cardiovascular disease represents one such strategy. In the U.S., obesity and OSA 
are both on the rise. But only about 20% of OSA is diagnosed, and even a smaller 
percentage is effectively treated [27-30]. OSA is a well-known independent risk factor 
for a variety of diseases related to cardiovascular disease, including hypertension, 
diabetes, cardiac arrhythmia, stroke, and coronary heart disease [5, 8, 9, 14, 31]. For 
these reasons, increasing the understanding of physiologic interactions among sleep-
related breathing parameters and the cardiovascular system is of substantial 
importance.  
 This project extends previous research by examining the prediction of 
cardiovascular and cerebrovascular outcomes, and is based on consideration of multiple 
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polysomnographic measures of sleep apnea severity (including frequency of apneic 
episodes, type of respiratory events, event duration, oxygen desaturation severity, and 
degree of sleep fragmentation). This research has the potential to refine the current 
concept of sleep apnea severity, by yielding a better understanding of prognosis for 
important clinical outcomes and by identifying key polysomnographic prognostic 
variables.  
 From the proposed research, a novel prognostic system will be developed and 
validated that will have clinical, policy, and research implications.  With respect to 
clinical care, this research will yield a better understanding of prognosis for individuals 
regarding clinical outcomes, which will help to inform treatment decisions.  The 
proposed work also has research implications. For example, knowledge of high risk 
groups will identify those most likely to benefit from treatment; thus, this study can 
serve as a prelude to future randomized controlled trials exploring the impact of sleep 
apnea therapy on the risk of cardiovascular outcomes. In addition, the research can 
further the understanding of the mechanisms mediating cardiovascular risk in patients 
with OSA, by identifying specific polysomnographic variables that explain variability in 
cardiovascular outcomes.   
 The DREAM study has several methodological strengths. The inclusion of 
participants from three different VA sites promotes population diversity, while 
maintaining consistency of access to government funded healthcare. The VA system has 
a robust electronic medical record system used at all sites, allowing for consistent and 
accurate adjudication of outcomes. Data were collected and scored using standardized 
criteria, with trained scorers at a central clinical research center, allowing for further 
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consistency and reliability. This method of research has the advantage of utilizing an 
established healthcare system and leveraging a robust electronic medical record for the 
collection of data. Of course, there are limitations to this approach as well, which 
include the use of billing codes as surrogate for cardiovascular outcome and selection 
bias inherent to collecting data based upon whether clinical follow-up occurred. CPAP 
compliance data was collected by documentation of a self-report through usual clinical 
care and also as surrogate of reissue of positive airway pressure supplies. 
To date, this project has assembled a large U.S. veteran sleep disorders “cohort,” 
and extensive polysomnographic data has been collected. As stated previously, the 
veteran population is particularly important to study the relationship between 
disordered sleep and cardiovascular disease, given that veterans are at high risk for 
having both cardiovascular disease and poor sleep, in part secondary to OSA. The 
primary limitation of the DREAM study database is the lack of gender diversity, which 
reflects the composition of the U.S. veteran population. For this reason, findings from 
this study have uncertain generalizability to women. 
 In summary, the DREAM study analyzes detailed sleep and breathing metrics for 
their association with outcomes of cardiovascular, cerebrovascular, and mortality 
events. A broad array of secondary outcomes will also be available, making this study 
applicable to other topics in neurology and psychiatry. The data from this study can 
provide valuable information regarding associations among different polysomnographic 
metrics of sleep apnea and cardiovascular outcomes.    
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TABLES 
 
Table 1. Inclusion and Exclusion Criteria 
INCLUSION CRITERIA EXCLUSION CRITERIA 
U.S. veteran in-lab PSG PSG to evaluate hypersomnia 
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Evaluation for SDB PSG to evaluate parasomnia 
Jan. 1, 2000-Dec 31, 2004 PAP Titration study 
History/physical in chart Tracheostomy 
At least 2 hours of PSG No follow-up after PSG 
PSG=polysomnography; SDB=sleep-disordered breathing; PAP=positive airway pressure 
 
 
 
 
 
 
Table 2. Polysomnographic Variables 
VARIABLES OPERATIONAL COMMENT TIME 
OBTAINED 
Respiratory    
Apnea  Hypopnea Index 
(AHI) 
# Respiratory Events / hour of 
total sleep time 
Zero time 
 Apnea Duration (sec) Mean and longest duration of  
respiratory events 
Zero time 
Hypoxia   
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Oxygen Desaturation 
Index 4% 
# oxygen desaturations ≥4%/ 
total sleep time 
Zero time 
Oxygen Desaturation 
Index 3% 
# oxygen desaturations ≥3%/ 
total sleep time 
Zero time 
T90 Percent of total sleep time with 
SaO2 <90% 
Zero time 
T80 Percent of total sleep time with 
SaO2 <80% 
Zero-time 
Average SaO2 Average oxygen saturation 
during sleep 
Zero-time 
Minimum SaO2 Lowest oxygen saturation   Zero-time 
Sympathetic Activity   
Arousal Index Total # arousals/hrs sleep  Zero-time 
Other   
Sleep duration Average number of sleep hours 
per night 
Pre-zero 
time 
Sleep Efficiency Total sleep time /time in bed Zero-time 
Periodic limb movement 
index 
Total # periodic limb 
movements / hour of sleep 
Zero-time 
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Epworth Sleepiness 
Scale 
Validated Clinical scale 
assessing sleepiness  
Pre-zero-
time 
 
 
 
 
 
 
 
 
Table 3: Risk Adjustment Variables 
VARIABLES OPERATIONAL 
COMMENT 
DATA 
SOURCE 
TIME 
OBTAINED 
VARIABLE 
TYPE 
Framingham 
Stroke 
    
Age In years Medical record Pre-zero time Dimensional 
Systolic BP (mmHg) BP prior to zero time  Medical Record Pre-zero time Dimensional 
Antihypertensive Rx Currently on any 
medication to treat high  
blood pressure 
Medical Record  Pre-zero time Binary 
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Diabetes Mellitus Diabetes history, on 
diabetic medication, or 
fasting blood sugar >126 
mg/dL 
Medical record Pre-zero time Binary 
Cigarette Smoking Any cigarette smoking at 
visit prior to zero time 
Medical record Pre-zero time Binary 
Cardiovascular 
Disease 
See Framingham Project Medial Record Pre-zero time Binary 
Atrial Fibrillation History atrial fibrillation  Medical Record Pre-zero time Binary 
Left Ventricular  
Hypertrophy 
By EKG Medical Record Pre-zero time Binary 
Framingham ACS     
Gender Male or Female Medical record Pre-zero time Binary 
Total  Cholesterol 
(mg/dL) 
avg. of two 
measurements obtained 
from lipoprotein analysis 
Medical record Pre-zero time Dimensional 
HDL Cholesterol 
(mg/dL) 
avg. of two 
measurements obtained 
from lipoprotein analysis 
Medical record Pre-zero time Dimensional 
Charlson Comorbidty Adjustment Medical Record Pre-zero time Dimensional 
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Comorbidity 
Index 
Additional 
Variables 
    
Race  Black ,White, Hispanic, 
Other 
PTF† Pre-zero time Nominal 
Socio-economic 
status 
Eligibility for VA services PTF† Pre-zero time Dimensional 
Sleep Apnea 
Treatment status 
Evidence of CPAP use, 
weight loss>20%,  
Medical record 
Prosthetic data 
Post-Zero 
time 
Binary 
† =Patient Treatment File 
 
Table 4. Primary Outcomes 
OUTCOMES OPERATIONAL COMMENT DATA SOURCE 
Primary 
Outcomes 
  
Acute Coronary     
Syndrome  
According to Guidelines of the  
American College of Cardiology22 
Medical record, 
PTF,* PCE  ,¥ VA-
Medicare   
Stroke Persistent focal neurologic deficit 
of presumed ischemic origin 
Medical record, 
PTF,* PCE ,¥ VA-
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lasting > than 24 hours  Medicare  
Transient Ischemic 
Attack  
   
Persistent focal neurologic deficit 
of presumed ischemic origin 
lasting < than 24 hours 
Medical record, 
PTF,* PCE ,¥ VA-
Medicare  
Death Patient died before 12/31/07 VA Vital Status  
*=Patient Treatment File 
¥=Patient Clinic Encounter 
 
 
 
 
 
 
 
Table 5. Baseline Characteristics of Cohort 
PARTICIPANT CHARACTERISTICS COHORT (N=1840) 
Age 58.1 ± 11.6 
Sex, male, n (%) 1268 (94.4) 
Race (n=1250) - 
    Caucasian, n (%) 1053 (84.2) 
    Black, n (%) 171 (13.7) 
    Hispanic, n (%) 26 (2.1) 
Body Mass Index, kg/m2 34.7 ± 6.8 
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Smoking Status, n (%) (n=1139) - 
    Never 374 (32.8) 
    Past 299 (26.3) 
    Current 466 (40.9) 
Drink alcohol, n (%) (n=1277) - 
    Never 449 (35.2) 
    Past 639 (50.0) 
    Current 189 (14.8) 
Atrial Fibrillation, n (%) 103 (7.7) 
Diabetes, n (%) 431 (32.1) 
Use of anti-hypertensive, n (%) 933 (70.2) 
Hypertension, n (%) 1184 (88.2) 
Apnea-hypopnea Index 18.6 ± 24.3 
Periodic Limb Movement Index 11.6 ± 23.7 
Arousal Index 42.4 ± 27.8 
 
 
